Pfizer has ended development of a B7-H4-directed antibody-drug conjugate (ADC), triggering a $1 billion impairment charge. The Big Pharma disclosed the blow alongside a $200 million charge linked ...
With the series win secured, it’s difficult not to be drawn to the performance of T1’s ADC, who continues to impress despite his controversial inclusion. Gumayusi has been a remarkably ...